A phase I Study of ecteinascidin 743(E) and capecitabine (C) in patients (pts) with advanced solid malignancies.

被引：0
|
作者：
Holden, SN
Rivera, E
Basche, M
Gore, L
Raj, SKS
O'Bryant, CL
Grolnic, S
Hunt, J
Brillhart, B
Van de Velde, H
Roberts, D
Rodgers, J
Eckhardt, SG
机构：
[1] Univ Colorado, Ctr Canc, Denver, CO 80202 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Johnson & Johnson Pharmaceut R&D, Beerse, Belgium
[4] Johnson & Johnson Pharmaceut R&D, Titusville, NJ USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6080S / 6080S
页数：1
相关论文
共 50 条
  • [1] Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies.
    Gore, L.
    Rivera, E.
    Lavallee, K.
    Holden, S.
    Grolnic, S.
    Cleere, D.
    Moulder, S. L.
    Elsayed, Y. A.
    Eckhardt, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 98S - 98S
  • [2] Phase I study of capecitabine (C) in combination with cisplatin (DDP) and irinotecan (IRI) in patients (pts) with advanced solid malignancies
    Sayar, H.
    Verschraegen, C. F.
    Smith, H.
    Rabinowitz, I.
    Lee, F. C.
    Shen, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] A phase I study of the oral platinum agent satraplatin (S) in with capecitabine (C) in patients (pts) with advanced solid malignancies
    Wisinski, K.
    Mulcahy, M.
    Kuzel, T. M.
    Benson, A. B., III
    Agulnik, M.
    MacVicar, G. R.
    Desai, D.
    Yun, S.
    Petrone, M.
    Gradishar, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A phase I combination study of irofulven (IROF) and gemcitabine (GEM) in patients (pts) with advanced solid malignancies.
    O'Bryant, CL
    Gore, L
    Long, M
    Gustafson, D
    Eppers, S
    Basche, M
    Rothenberg, M
    Weems, G
    Shah, A
    Herdrich, L
    Eckhardt, SG
    Berlin, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9119S - 9120S
  • [5] A phase I, pharmacological and biological study of the farnesyl transferase inhibitor (FTI) R115977 and capecitabine in patients (pts) with advanced solid malignancies.
    Holden, SN
    Cohen, R
    Fisher, S
    Persky, M
    Mikule, C
    Morrow, M
    Richards, H
    Rodriguez, S
    Eckhardt, SG
    CLINICAL CANCER RESEARCH, 2000, 6 : 4573S - 4573S
  • [6] A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies
    Villalona-Calero, MA
    Eckhardt, SG
    Weiss, G
    Hidalgo, M
    Beijnen, JH
    van Kesteren, C
    Rosing, H
    Campbell, E
    Kraynak, M
    Lopez-Lazaro, L
    Guzman, C
    Von Hoff, DD
    Jimeno, J
    Rowinsky, EK
    CLINICAL CANCER RESEARCH, 2002, 8 (01) : 75 - 85
  • [7] Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies.
    Dupont, J
    Schwartz, L
    Koutcher, J
    Spriggs, D
    Gordon, M
    Mendelson, D
    Murren, J
    Lucarelli, A
    Cedarbaum, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 197S - 197S
  • [8] Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies.
    Mittal, Kriti
    Koon, Henry B.
    Elson, Paul
    Triozzi, Pierre L.
    Dowlati, Afshin
    Borden, Ernest C.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] A phase I study of the heparanase inhibitor: PI-88 and weekly docetaxel in patients (PTS) with advanced solid malignancies.
    Raj, SKS
    Basche, M
    Gore, L
    Grolnic, S
    Hunt, J
    O'Bryant, CL
    Morrow, M
    Creese, B
    Kangas, M
    Sawlwin, D
    Eckhardt, SG
    Holden, SN
    Holden, SN
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6152S - 6152S
  • [10] Phase I trial of SNS-595 in patients (pts) with advanced malignancies.
    Advani, R
    Gordon, M
    Hurwitz, H
    Mendelson, D
    Wakelee, H
    Ebbinghaus, S
    Hoch, U
    Silverman, J
    Havrilla, N
    Adelman, D
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9056S - 9056S
12345